블로그

Kisqali: 유방암의 1차 치료 옵션

Group of women wearing breast cancer awareness ribbons

Kisqali is an oral medication used to treat certain types of advanced or metastatic breast cancer. It is considered a first-line treatment option. It is also effective in extending survival when combined with hormone therapy.

화학요법 공제금 지원 받기

화학요법 재정 지원
(877) 778-0318

Novartis, a Swiss multinational pharmaceutical company, developed Kisqali. It works by blocking specific enzymes that promote cancer cell division. 

The drug was discovered in the late 2000s as part of a research program to find inhibitors of cyclin-dependent kinases (CDKs). CDKs are enzymes involved in cell cycle regulation. Novartis recognized Kisqali’s potential as a cancer therapy and began clinical trials in breast cancer patients in 2013. In March 2017, the 식품의약국(FDA) approved the drug for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women. Later that year, the drug was approved for the same indication in Europe. The FDA expanded its approval to include premenopausal and perimenopausal women in July 2018.

Since its approval, Kisqali has become a great treatment option for advanced and metastatic breast cancer patients. 

What Is Kisqali Used To Treat?

Kisqali is a brand-name prescription drug used to treat an advanced type of breast cancer in women. It is used to treat breast cancer that has all the following properties [1]:

  • Metastatic or locally advanced: Kisqali can treat breast cancer that is advanced (metastatic) or locally advanced. Metastatic means that the cancer has spread to different body parts, including the bones, liver, brain, and lungs. Locally advanced means that the cancer has spread to the breast area and structures, such as nearby lymph nodes, muscle, and skin, but not to other body parts.
  • Hormone receptor-positive (HR-positive): Kisqali can help with hormone receptor positive (HR+) breast cancer. 
  • HER2-negative (HER2-): Kisqali can help with a type of breast cancer that does not have the human epidermal growth factor receptor (HER2-).

Note: Kisqali’s safety and effectiveness in children are unknown. 

How Kisqali Works

Kisqali is used to treat specific types of breast cancer. The active component in Kisqali is ribociclib. It works by inhibiting enzymes called CDK4 and CDK6. These enzymes regulate cell development in both cancerous and normal cells. These enzymes can become hyperactive in cancer cells, leading them to divide and grow uncontrollably. By blocking these enzymes, Kisqali can reduce or stop the growth of cancer cells in the body.

부작용

Like all medications, Kisqali can also cause side effects. In rare cases, it can also cause some severe side effects. The FDA has warned that Kisqali could cause fatal lung problems [7]. 

Here are some mild to severe side effects [1]:

Mild Side Effects

Woman with back pain as a side effect of taking Kisqali

The following are some of the most common mild side effects of using Kisqali:

  • 메스꺼움
  • 허리 통증
  • 피로
  • 구토
  • 설사
  • 변비
  • 탈모
  • Low white blood cell counts
  • 두통

Most of these side effects may disappear within a few days or weeks. Consult your doctor or pharmacist if they become more severe or do not go away.

Serious Side Effects

As stated earlier, serious side effects are rare but can occur. If you experience any of the listed serious side effects, contact your doctor immediately. 

Serious side effects can include:

Heart problems: Kisqali can cause abnormal heartbeat, leading to death. Symptoms can include dizziness, fast heartbeat, faintness, and irregular heartbeat.

Liver problems: Severe liver problems can occur during treatment. Performing liver function tests before and during treatment is important. Symptoms of liver problems include loss of appetite, yellowing of your skin or the whites of your eyes, stomach pain, and dark urine.

Lung problems: You may encounter severe lung problems during Kisqali treatment, leading to death. Signs of the problem may be difficulty breathing, pain in the chest, and coughing.

Low white blood cell counts: While using Kisqali, low white blood cell counts are common and can lead to dangerous infections.

Severe skin problems: You may experience a severe rash that progressively worsens. Symptoms can include red or flushed skin, peeling skin, blisters, fever, and body aches.

Please note that the list of side effects provided is not comprehensive. Seek immediate medical attention if you experience any severe side effects.

화학요법 전문가와 상담하세요

화학 요법 치료 지원 받기
상담 일정을 잡으세요

Dosage and Treatment

Kisqali is available in a 200 mg tablet form. The duration of one treatment cycle is 4 weeks. During the first 3 weeks of the cycle, three tablets totaling 600 mg are administered once daily with or without food. After the 3-week period, there is a 1-week break before the next cycle begins.

Note: If severe side effects occur, your doctor can lower your dose or stop the treatment.

Before Taking Kisqali

Kisqali should not be used if you are allergic to ribociclib or if you are also taking tamoxifen. Your doctor will order blood tests to check that you do not have any issues that might prevent you from safely taking Kisqali.

To ensure that the medication is safe for you, inform your doctor if you have ever had:

  • Slow heartbeats
  • A history of heart disease or a previous heart attack
  • Long QT syndrome
  • Liver disease
  • Kidney disease
  • Signs of infection (fever, chills)

Also, let your doctor know if you’ve gone through menopause. You may need to have a negative pregnancy test before starting this treatment.

Kisqali Cost

According to the official website, Kisqali tablets can cost around $6,000 to $15,000 per month, depending on your dose [5]. But the treatment’s actual cost depends on your insurance plan, location, and the pharmacy you visit. 문의하기 if you are interested in copay or financial assistance. 

전문가와 상담하세요

공제금 지원에 관하여
(877) 778-0318

자주 묻는 질문

Here are answers to frequently asked questions about Kisqali:

Is Kisqali a kind of chemotherapy?

Yes. It is an oral chemotherapy drug that signals cancer cells to stop growing.

Is Kisqali safe to use during pregnancy?

Kisqali is not recommended during pregnancy because it could harm your unborn child. If you are a female of reproductive age taking Kisqali, you should take birth control during treatment and for 3 weeks after the last dosage. If you become pregnant while using this medicine, inform your healthcare provider immediately.

Is it safe to take Kisqali while breastfeeding?

Breastfeeding is not recommended while using Kisqali. We don’t know if the medicine can pass into your breast milk. But if it does, breastfeeding infants are in danger of serious harm. You should not breastfeed while taking this medication and for 3 weeks after your final dosage because of this risk. Talk with your provider about other options for feeding your baby during therapy. 

What are the clinical benefits of Kisqali?

Kisqali is a drug that is used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in women. It has some benefits over traditional treatments. Here are some clinical benefits of Kisqali:

  • It can improve overall survival when used as a first-line treatment. According to a study, women treated with Kisqali and endocrine therapy lived about 1 year longer than women treated with endocrine therapy alone [8].
  • It can also improve progression-free survival. According to a study, women treated with Kisqali and letrozole had 9 months of more progression-free survival than women treated with letrozole alone [8].
  • Kisqali can improve the quality of life for patients [9].

Can Kisqali cause me to lose my hair?

Possibly. Hair loss is a very common side effect. Hair loss was reported in up to 33% of patients taking Kisqali in conjunction with other hormone treatments in studies [6]. If you are concerned about hair loss, talk with your provider.

참고문헌:

  1. KISQALI® (ribociclib) for HR+, HER2- Metastatic Breast Cancer. (n.d.). https://www.us.kisqali.com/metastatic-breast-cancer/
  2. HIGHLIGHTS OF PRESCRIBING INFORMATION. (n.d.). https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf
  3. Office of the Commissioner. (2018). FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency. U.S. Food And Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-drug-through-new-oncology-review-pilot-enables-greater-development#:~:text=Kisqali%20was%20first%20approved%20in,other%20parts%20of%20the%20body.
  4. Ribociclib Approval Expanded for Breast Cancer. (2018, August 20). National Cancer Institute. https://www.cancer.gov/news-events/cancer-currents-blog/2018/ribociclib-fda-expanded-approval-breast-cancer
  5. Cost Information | KISQALI® (ribociclib) Cost. (n.d.). https://www.patient.novartisoncology.com/kisqali-cost/
  6. DailyMed – KISQALI- ribociclib tablet, film coated. (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8
  7. ResearchU.S. Food And Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer
  8. Ribociclib Improves Survival in Advanced Breast Cancer. (2021, October 6). National Cancer Institute. https://www.cancer.gov/news-events/cancer-currents-blog/2021/ribociclib-improves-metastatic-breast-cancer-survival
  9. Admin. (2017, March 15). Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer. Clinical Trials Arena. https://www.clinicaltrialsarena.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2-metastatic-breast-cancer/
이 정보는 의학적 조언이나 치료를 대체할 수 없습니다. 새로운 치료를 시작하기 전에 담당 의사 또는 의료 서비스 제공자와 건강 상태에 대해 상담하십시오. AmeriPharma® Specialty Care는 제공된 정보 또는 그 결과로 내려진 진단이나 치료에 대해 어떠한 책임도 지지 않으며, 콘텐츠의 신뢰성에 대해서도 책임을 지지 않습니다. AmeriPharma® Specialty Care는 여기에 나열된 모든 웹사이트/기관을 운영하는 것은 아니며, 해당 콘텐츠의 가용성이나 신뢰성에 대해서도 책임을 지지 않습니다. 이러한 목록은 AmeriPharma® Specialty Care의 보증, 후원 또는 추천을 암시하거나 구성하지 않습니다. 이 웹페이지에는 AmeriPharma® Specialty Care와 제휴하지 않은 제약 회사의 상표 또는 등록 상표인 브랜드 처방약에 대한 참조가 포함될 수 있습니다.
의학적으로 검토됨 Christine Leduc 박사, PharmD

크리스틴 레덕 약학박사는 캘리포니아주 어바인에서 태어나고 자랐습니다. 미드웨스턴 대학교를 우등으로 졸업했습니다. 그녀의 업무에서 가장 보람 있는 부분은 생활 습관 변화를 제안하고, 환자에게 약물의 작용 원리를 교육하고, 미래의 약사들을 지도하는 것입니다. 그녀의 전문 분야는 고객 서비스와 특수 약물에 대한 지식입니다. 과거 서비스 업계에서 일한 경험을 통해 환자의 요구를 이해하는 데 필요한 고객 서비스 기술을 습득했습니다. 레덕 박사는 현재 마셜 B. 케첨 대학교, 캔자스 대학교, 미드웨스턴 대학교에서 학생들을 지도하고 있습니다. 여가 시간에는 여행, 베이킹, 정원 가꾸기를 즐깁니다. 저자 약력 보기

문의하기

아래 HIPAA 규격 양식을 사용하여 처방전 재조제를 요청하세요. 복용 중인 약이나 복용 방법에 대한 문의 사항이 있으시면 문의하기 페이지를 방문하시거나 다음 번호로 전화해 주세요. (877) 778-0318.

HIPAA Compliant

제출하면 AmeriPharma에 동의하는 것입니다. 이용 약관, 개인정보 보호정책, 그리고 개인정보 보호 관행 고지

ko_KRKorean